Due to the more extensive requireies following the adoption of the IFRS in the upcoming Annual report of 2021/2022, we herby postphone our annual general meeting til Tuesday the 14th of
Monday the 31th of January, we will send out the Notice of the Annual general meeting followed by the publication of the Annual Report of 2021/2022.
For more information about
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
We research, develop, manufacture, commercialize and brand over-the-counter (OTC) products under pharmaceutical legislation. Currently, 21 products with cannabidiol aimed at autoimmune and stress-related diseases have been developed. The first products reached Danish stores in 2020, and now 9 products are available on the European market at more than 500 points of sale. Another 12 products will be launched before the end of 2024, with 11 patent-pending products. The product line surpasses competing products on the market by being located at the intersection of natural products, science, and cannabinoid technology while being registered under pharmaceutical legislation.
https://news.cision.com/cs-medica-a-s/r/postponement-of-annual-general-meeting,c3704704
(c) 2023 Cision. All rights reserved., source